Last reviewed · How we verify

NCT00492167

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Completed Phase 1 Last updated 7 March 2022
What this trial tests

Phase 1 trial testing beta-glucan in Neuroblastoma in 45 participants. Completed in 4 March 2022.

Timeline
9 September 2005
Primary endpoint
4 March 2022
4 March 2022

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment45
Start date9 September 2005
Primary completion4 March 2022
Estimated completion4 March 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

Adults 0 to 120, any sex, with Neuroblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Beta-glucan may stimulate the immune system and stop tumor cells from growing. Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving beta-glucan together with monoclonal antibody 3F8 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan when given together with monoclonal antibody 3F8 in treating patients with metastatic neuroblastoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Tumor-associated macrophages: from basic research to clinical application.
    Yang L, Zhang Y. · · 2017 · cited 654× · PMID 28241846 · DOI 10.1186/s13045-017-0430-2
  2. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.
    Nazha B, Inal C, Owonikoko TK. · · 2020 · cited 234× · PMID 32733795 · DOI 10.3389/fonc.2020.01000
  3. Anti-GD2 immunotherapy for neuroblastoma.
    Sait S, Modak S. · · 2017 · cited 155× · PMID 28780888 · DOI 10.1080/14737140.2017.1364995
  4. Tumor-Associated Macrophages as Target for Antitumor Therapy.
    Sawa-Wejksza K, Kandefer-Szerszeń M. · · 2018 · cited 145× · PMID 28660349 · DOI 10.1007/s00005-017-0480-8
  5. β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application.
    Murphy EJ, Rezoagli E, Major I, Rowan NJ, et al · · 2020 · cited 121× · PMID 33322069 · DOI 10.3390/jof6040356
  6. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies.
    Zhu S, Yi M, Wu Y, Dong B, et al · · 2021 · cited 116× · PMID 34965886 · DOI 10.1186/s40164-021-00252-z
  7. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.
    Kushner BH, Cheung IY, Modak S, Kramer K, et al · · 2014 · cited 105× · PMID 24520094 · DOI 10.1158/1078-0432.ccr-13-1012
  8. Yeast-Derived β-Glucan in Cancer: Novel Uses of a Traditional Therapeutic.
    Geller A, Shrestha R, Yan J. · · 2019 · cited 95× · PMID 31344853 · DOI 10.3390/ijms20153618

Verify or expand the search:

Other recruiting trials for Neuroblastoma

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00492167.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing